MA52504A - Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations - Google Patents

Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations

Info

Publication number
MA52504A
MA52504A MA052504A MA52504A MA52504A MA 52504 A MA52504 A MA 52504A MA 052504 A MA052504 A MA 052504A MA 52504 A MA52504 A MA 52504A MA 52504 A MA52504 A MA 52504A
Authority
MA
Morocco
Prior art keywords
type
binding proteins
receptor binding
cannabinoid receptor
cannabinoid
Prior art date
Application number
MA052504A
Other languages
English (en)
French (fr)
Inventor
Antara Banerjee
Andrea Fanjul
Robert J Hoey
Kacey Sachen
Nikolai Suslov
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA52504A publication Critical patent/MA52504A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MA052504A 2018-04-30 2019-04-29 Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations MA52504A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862664882P 2018-04-30 2018-04-30

Publications (1)

Publication Number Publication Date
MA52504A true MA52504A (fr) 2021-04-28

Family

ID=67396963

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052504A MA52504A (fr) 2018-04-30 2019-04-29 Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations

Country Status (21)

Country Link
US (3) US12202901B2 (cg-RX-API-DMAC7.html)
EP (1) EP3787746A1 (cg-RX-API-DMAC7.html)
JP (3) JP7431750B2 (cg-RX-API-DMAC7.html)
KR (1) KR102992188B1 (cg-RX-API-DMAC7.html)
CN (1) CN112218684A (cg-RX-API-DMAC7.html)
AR (1) AR114436A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019264029B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020022035A2 (cg-RX-API-DMAC7.html)
CA (1) CA3098416A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002793A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020014681A2 (cg-RX-API-DMAC7.html)
EA (1) EA202092593A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20076576A (cg-RX-API-DMAC7.html)
IL (1) IL278276B2 (cg-RX-API-DMAC7.html)
MA (1) MA52504A (cg-RX-API-DMAC7.html)
MX (1) MX2020011498A (cg-RX-API-DMAC7.html)
PE (1) PE20210419A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551805A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202010388SA (cg-RX-API-DMAC7.html)
TW (1) TWI882957B (cg-RX-API-DMAC7.html)
WO (1) WO2019211665A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7431750B2 (ja) 2018-04-30 2024-02-15 武田薬品工業株式会社 カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用
AU2023249518A1 (en) * 2022-04-04 2024-10-17 Bird Rock Bio Sub, Inc. Prediction and treatment of fast progressing renal disease
EP4534672A1 (en) 2022-06-03 2025-04-09 Shionogi & Co., Ltd Antibody that binds to cannabinoid type 1 receptors
EP4539845A1 (en) * 2022-06-17 2025-04-23 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Peripheralization of centrally-acting cannabinoid-1 receptor antagonists by nanoparticles for the treatment metabolic related conditions
WO2024022478A1 (zh) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途
WO2025257151A1 (en) * 2024-06-10 2025-12-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating ciliopathies

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
WO2005023232A2 (en) 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
CA2915386A1 (en) * 2013-06-26 2014-12-31 Amgen Inc. Cb1 receptor antigen-binding proteins and uses thereof
KR102731863B1 (ko) 2014-03-27 2024-11-19 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
US10277406B1 (en) * 2014-09-05 2019-04-30 Digicert, Inc. Authentication process for issuing sequence of short-lived digital certificates
US10034865B2 (en) 2015-09-10 2018-07-31 Kashiv Pharma, Llc Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof
CA3000167A1 (en) * 2015-09-30 2017-04-06 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor
EP3490542A4 (en) 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
JP7431750B2 (ja) 2018-04-30 2024-02-15 武田薬品工業株式会社 カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用

Also Published As

Publication number Publication date
US20210198358A1 (en) 2021-07-01
ECSP20076576A (es) 2021-12-30
EP3787746A1 (en) 2021-03-10
US20220396620A1 (en) 2022-12-15
CO2020014681A2 (es) 2020-12-10
IL278276B1 (en) 2026-02-01
JP2024059646A (ja) 2024-05-01
EA202092593A1 (ru) 2021-02-12
PH12020551805A1 (en) 2021-07-26
MX2020011498A (es) 2021-01-29
US20250250341A1 (en) 2025-08-07
IL278276A (cg-RX-API-DMAC7.html) 2020-12-31
US11746155B2 (en) 2023-09-05
CL2020002793A1 (es) 2021-02-12
JP2026076162A (ja) 2026-05-11
US12202901B2 (en) 2025-01-21
JP7798931B2 (ja) 2026-01-14
KR102992188B1 (ko) 2026-07-15
PE20210419A1 (es) 2021-03-08
JP2021525059A (ja) 2021-09-24
WO2019211665A1 (en) 2019-11-07
TWI882957B (zh) 2025-05-11
KR20210005051A (ko) 2021-01-13
AU2019264029A1 (en) 2020-11-19
TW202003549A (zh) 2020-01-16
CA3098416A1 (en) 2019-11-07
SG11202010388SA (en) 2020-11-27
CN112218684A (zh) 2021-01-12
IL278276B2 (en) 2026-06-01
AU2019264029B2 (en) 2026-06-04
BR112020022035A2 (pt) 2021-02-02
JP7431750B2 (ja) 2024-02-15
AR114436A1 (es) 2020-09-02

Similar Documents

Publication Publication Date Title
EP3891181A4 (en) BINDING MOLECULES AGAINST CD3 AND USES THEREOF
EP3612218A4 (en) TREM2 ANTIGENT BINDING PROTEINS AND USES THEREOF
EP3902838A4 (en) Cd30-binding moieties, chimeric antigen receptors, and uses thereof
EP3426680A4 (en) ACTIVIN TYPE 2 RECEPTOR BINDING PROTEINS AND USES THEREOF
EP3710484A4 (en) CTLA-4 BINDING ANTIBODIES AND USES THEREOF
EP3997230A4 (en) Claudin-6 binding molecules and uses thereof
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
EP3802581A4 (en) MULTISPECIFIC BINDING PROTEINS AND IMPROVEMENTS THERETO
EP3538150A4 (en) FOR ASCT2-SPECIFIC BINDING MOLECULES AND USE THEREOF
EP3359576A4 (en) ANTIGENBINDING POLYPEPTIDE CONSTRUCTS WITH KAPPA AND LAMBDA LIGHT CHAINS AND USES THEREOF
MA53094A (fr) Protéine de liaison à l'antigène anti-steap1
EP4200336A4 (en) Anti-ror1 antibodies and related bispecific binding proteins
EP3717505A4 (en) GENENICALLY MODIFIED DNA-BINDING PROTEINS
EP3442574A4 (en) Novel B7-H3 binding MOLECULES, ANTIBODY-ACTIVE CONJUGATES AND METHOD OF USE THEREOF
EP3328994A4 (en) CD56 TARGETING ANTIGEN BINDING PROTEINS AND USES THEREOF
EP3732564A4 (en) ASYNCHRONE C-JS DATA BINDING BRIDGE
MA42059A (fr) Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
SG11202010388SA (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
EP3445394A4 (en) ALK7-BINDING PROTEINS AND THEIR USE
EP3743448A4 (en) XCR1 BINDING AGENTS AND USES THEREOF
EP3700571A4 (en) ALK7-BINDING PROTEINS AND USES THEREOF
EP3515948A4 (en) PROTEIN-BINDING PROTEINS AND USES THEREOF
EP3719035A4 (en) POLYPEPTIDE WITH ANTIGEN-BINDING AREA AND CARRYING SECTION
EP3864025A4 (en) POLYPEPTIDES WITH A BETA-TRICALCIUM PHOSPHATE BINDING SEQUENCE AND THEIR USES
EP3797164A4 (en) CHIMERIC ANTIGEN RECEPTORS WITH MODIFIED LINKER DOMAINS AND THEIR USES